Enanta Pharmaceuticals, Inc. Common Stock ENTA
i
Market dataready · fetched 2026-11-06T20:54:21.615Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T20:53:57.739905383Z
FundamentalsSEC EDGAR · ready · as of 2026-06-30 · fetched 2026-11-06T20:54:21.228635+00:00
Enanta Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 9.17 | 105.6% | 19.3% | |||
| 25Δ | 9.65 | 105.3% | 15.6% | |||
| 30Δ | 10.12 | 108.7% | 12.8% | |||
| 35Δ | 10.56 | 121.8% | 12.1% | |||
| 40Δ | 11.60 | 87.8% | 11.6% | 10.99 | 134.8% | 11.4% |
| 45Δ | 11.34 | 90.6% | 10.4% | 11.42 | 147.9% | 10.7% |
| 50Δ | 11.09 | 93.4% | 9.2% | 11.86 | 160.9% | 10.0% |
| 55Δ | 10.83 | 96.2% | 8.1% | 12.29 | 174.0% | 9.3% |
| 60Δ | 10.58 | 99.0% | 6.9% | 12.92 | 183.0% | 8.3% |
| 65Δ | 10.32 | 101.8% | 5.8% | 13.72 | 188.2% | 7.0% |
| 70Δ | 10.07 | 104.6% | 4.6% | 14.52 | 193.4% | 5.8% |
| 75Δ | 16.22 | 218.9% | 4.9% | |||
| 80Δ | 19.84 | 271.5% | 4.4% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.17
- IV
- 105.6%
- B/E move
- 19.3%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.65
- IV
- 105.3%
- B/E move
- 15.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.12
- IV
- 108.7%
- B/E move
- 12.8%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.56
- IV
- 121.8%
- B/E move
- 12.1%
40Δ
- Pseudo strike
- 11.60
- IV
- 87.8%
- B/E move
- 11.6%
- Pseudo strike
- 10.99
- IV
- 134.8%
- B/E move
- 11.4%
45Δ
- Pseudo strike
- 11.34
- IV
- 90.6%
- B/E move
- 10.4%
- Pseudo strike
- 11.42
- IV
- 147.9%
- B/E move
- 10.7%
50Δ
- Pseudo strike
- 11.09
- IV
- 93.4%
- B/E move
- 9.2%
- Pseudo strike
- 11.86
- IV
- 160.9%
- B/E move
- 10.0%
55Δ
- Pseudo strike
- 10.83
- IV
- 96.2%
- B/E move
- 8.1%
- Pseudo strike
- 12.29
- IV
- 174.0%
- B/E move
- 9.3%
60Δ
- Pseudo strike
- 10.58
- IV
- 99.0%
- B/E move
- 6.9%
- Pseudo strike
- 12.92
- IV
- 183.0%
- B/E move
- 8.3%
65Δ
- Pseudo strike
- 10.32
- IV
- 101.8%
- B/E move
- 5.8%
- Pseudo strike
- 13.72
- IV
- 188.2%
- B/E move
- 7.0%
70Δ
- Pseudo strike
- 10.07
- IV
- 104.6%
- B/E move
- 4.6%
- Pseudo strike
- 14.52
- IV
- 193.4%
- B/E move
- 5.8%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 16.22
- IV
- 218.9%
- B/E move
- 4.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 19.84
- IV
- 271.5%
- B/E move
- 4.4%
Options history
Table
| Date | IV (%) |
|---|---|
| 93.29% | |
| 78.86% | |
| 74.82% | |
| 78.11% | |
| 84.24% | |
| 84.78% | |
| 85.35% | |
| 83.43% | |
| 76.91% | |
| 93.43% | |
| 112.41% | |
| 140.94% | |
| 82.16% | |
| 81.67% | |
| 78.70% | |
| 78.75% | |
| 87.60% | |
| 91.74% | |
| 91.04% | |
| 97.59% | |
| 92.90% | |
| 92.95% | |
| 103.37% | |
| 108.68% | |
| 112.81% | |
| 105.03% | |
| 135.25% | |
| 206.19% | |
| 99.65% | |
| 87.09% | |
| 95.98% | |
| 97.14% | |
| 95.03% | |
| 94.19% | |
| 98.25% | |
| 94.72% | |
| 92.46% | |
| 99.94% | |
| 108.43% |
Biotechnology
ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →EVMN
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in…
More →EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Description unavailable
More →EYPT
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United…
More →